EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC 4.0

Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model

Marga A G Helmink iD, Steven H J Hageman iD, Björn Eliasson iD, Naveed Sattar iD, Frank L J Visseren iD, Jannick A N Dorresteijn iD, Katie Harris, Sanne A E Peters iD, Mark Woodward iD, Péter Szentkúti, Kurt Højlund iD, Jan Erik Henriksen iD und 5 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15531 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Marga A G Helmink und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Cardiovascular Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To develop and externally validate the LIFE‐T1D model for the estimation of lifetime and 10‐year risk of cardiovascular disease (CVD) in individuals with type 1 diabetes. Materials and Methods A sex‐specific competing risk‐adjusted Cox proportional hazards model was derived in individuals with type 1 diabetes without prior CVD from the Swedish National Diabetes Register (NDR), using age as the time axis. Predictors included age at diabetes onset, smoking status, body mass index, systolic blood pressure, glycated haemoglobin level, estimated glomerular filtration rate, non‐high‐density lipoprotein cholesterol, albuminuria and retinopathy. The model was externally validated in the Danish Funen Diabetes Database (FDDB) and the UK Biobank.

Results

During a median follow‐up of 11.8 years (interquartile interval 6.1–17.1 years), 4608 CVD events and 1316 non‐CVD deaths were observed in the NDR ( n = 39 756). The internal validation c‐statistic was 0.85 (95% confidence interval [CI] 0.84–0.85) and the external validation c‐statistics were 0.77 (95% CI 0.74–0.81) for the FDDB ( n = 2709) and 0.73 (95% CI 0.70–0.77) for the UK Biobank ( n = 1022). Predicted risks were consistent with the observed incidence in the derivation and both validation cohorts.

Conclusions

The LIFE‐T1D model can estimate lifetime risk of CVD and CVD‐free life expectancy in individuals with type 1 diabetes without previous CVD. This model can facilitate individualized CVD prevention among individuals with type 1 diabetes. Validation in additional cohorts will improve future clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Cardiovascular DiseasesHumansMaleFemaleAdultMiddle AgedRisk AssessmentSwedenProportional Hazards ModelsRegistriesDiabetic AngiopathiesFollow-Up StudiesDenmarkRisk FactorsGlycated HemoglobinHeart Disease Risk FactorsUnited KingdomAge of OnsetBody Mass Index

Stichwörter der Autor:innen

cardiovascular diseasediabetes complicationsmacrovascular diseasetype 1 diabetes

Substanzen

Glycated Hemoglobin

Autor:innen und Institutionen

  • Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • School of Cardiovascular and Metabolic Sciences, University of Glasgow, Glasgow, UK.
  • The George Institute for Global Health, University of New South Wales, Sydney, Australia.
  • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
  • The George Institute for Global Health, Imperial College London, London, UK.

ORCID-Profile: Marga A G Helmink, Steven H J Hageman, Björn Eliasson, Naveed Sattar, Frank L J Visseren, Jannick A N Dorresteijn, Sanne A E Peters, Mark Woodward, Kurt Højlund, Jan Erik Henriksen, Henrik Toft Sørensen, Erik H Serné, Thomas T van Sloten, Reimar W Thomsen, Jan Westerink

Zitieren

APA

Helmink, M. A. G., Hageman, S. H. J., Eliasson, B., Sattar, N., Visseren, F. L. J., Dorresteijn, J. A. N., Harris, K., Peters, S. A. E., Woodward, M., Szentkúti, P., Højlund, K., Henriksen, J. E., Sørensen, H. T., Serné, E. H., van Sloten, T. T., Thomsen, R. W., & Westerink, J. (2024). Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15531

Vancouver

Helmink MAG, Hageman SHJ, Eliasson B, Sattar N, Visseren FLJ, Dorresteijn JAN, et al. Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15531

BibTeX
@article{Helmink2024,
  author = {Helmink, Marga A G and Hageman, Steven H J and Eliasson, Björn and Sattar, Naveed and Visseren, Frank L J and Dorresteijn, Jannick A N and Harris, Katie and Peters, Sanne A E and Woodward, Mark and Szentkúti, Péter and Højlund, Kurt and Henriksen, Jan Erik and Sørensen, Henrik Toft and Serné, Erik H and van Sloten, Thomas T and Thomsen, Reimar W and Westerink, Jan},
  title = {Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15531}
}
Kostenlos starten →